Ozempic

Novo Nordisk (NYSE:NVO) has appealed to the U.S. Food and Drug Administration (FDA) to halt the production of compounded versions of its drugs Wegovy and Ozempic by compounding pharmacies. These cheaper alternatives have been under scrutiny due to potential safety risks and lack of FDA approval....

Novo Nordisk A/S (NYSE:NVO) just hit a technical red flag — a Death Cross. Chart created using Benzinga Pro For those uninitiated, this bearish signal occurs when a stock's 50-day moving average drops below its 200-day moving average, hinting that more downside could be ahead. However, Novo...

A recent real-world data analysis was conducted to suggest a link between glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) prescriptions and reduced rates of opioid overdose and alcohol intoxication among patients with opioid use disorder (...

The Federal Reserve's preferred measure of inflation, the personal consumption expenditures index, grew less than economists expected in August at 2.2% year-over-year. The data comes on the heels of the Federal Reserve's 0.5% interest rate cut issued Sept. 18, the first in more than four years....

Some experts believe Novo Nordisk A/S (NYSE:NVO) products not only help people lose weight and control diabetes, they can help treat the country’s addiction crisis. The Novo Nordisk chart illustrates two common technical analysis dynamics that successful traders can use to profit. As you can...

A study compared the association of semaglutide vs other antidiabetic medications and other GLP-1RAs, including liraglutide and dulaglutide, with opioid overdose risk in patients with comorbid type 2 diabetes (T2D) and opioid use disorder (OUD). Novo Nordisk A/S’ (NYSE:NVO) semaglutide is...

A new study has found that people with a history of opioid abuse who took Novo Nordisk‘s (NYSE:NVO) Ozempic weight loss drug were significantly less likely to overdose, adding to growing evidence suggesting that the drug, primarily used for diabetes and weight loss, could help manage drug...

Novo Nordisk A/S (NYSE:NVO) is under mounting political pressure over the high U.S. prices of its blockbuster weight-loss drugs, Ozempic and Wegovy, as the race for the White House heats up. The pricing disparity between the U.S. and other international markets has drawn sharp criticism from...

Novo Nordisk A/S (NYSE:NVO) will consider ways to help patients get affordable prescriptions for weight loss drugs, CEO Lars Fruergaard Jorgensen told members of the U.S. Congress on Wednesday when asked if his company would lower U.S. prices for Ozempic and Wegovy. Jorgensen sat before the Health...

Novo Nordisk's (NYSE:NVO) CEO Lars Fruergaard Jorgensen, has revealed that their diabetes medication and often hailed as a “miracle” weight loss drug, Ozempic will soon be eligible for U.S. government price negotiations, potentially within the next year. What Happened: Jorgensen is...

Editor’s Note: This story has been updated to include a statement from a Novo Nordisk spokesperson. Sen. Bernie Sanders (I-Vt.) has once again criticized Novo Nordisk A/S (NYSE:NVO) for the high price of its diabetes drug, Ozempic, in the United States. What Happened: On Sunday, Sanders took...

Criminals are distributing fake versions of the weight-loss drug Ozempic by forging the drug batch numbers pharmaceutical companies use to authenticate drugs and track them in a specified country. They obtain batch numbers illicitly through a liaison who works at a drugmaker factory or by buying...

Researchers are now suggesting that a drug for Type 2 diabetes and obesity might actually have anti-aging powers. Harlan Krumholz of the Yale School of Medicine declared that semaglutide, marketed as Ozempic, could be a game-changer with benefits far beyond our wildest dreams after several...

The rivalry between Novo Nordisk A/S (NYSE:NVO) and Eli Lilly and Co (NYSE:LLY) has heated up as both companies vie for dominance in the booming obesity-drug market. But for investors, the real story may lie beyond just weight-loss treatments. Novo Nordisk & Eli Lilly – Expanding Beyond...

Shares of the weight-loss giant Novo Nordisk A/S (NYSE:NVO) are plunging by over 6% during Wednesday morning trading in New York, in response to the quarterly results released during the premarket. What Happened: Novo Nordisk reported second-quarter 2024 sales of DKK 68.06 billion ($9.972 billion...